CPI-613 (Devimistat) |
Catalog No.GC14921
One-Click Copy Product Info
|
An inhibitor of α-ketoglutarate dehydrogenase
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 95809-78-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CPI-613 is a first-in-class anti-cancer agent [1].
CPI-613 is developed to target the pyruvate dehydrogenase complex which is a key mitochondrial enzyme of anaerobic glycolysis in tumor cells. The pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) play critical roles in the interconversion of both pyruvate and alpha-ketoglutarate to key biosynthetic intermediates in mitochondrial carbon metabolism process. The complex of the two enzymes requires lipoate to be as a co-factor. CPI-613 is a derivative of lipoate and therefore inhibits the energy metabolism in mitochondria [1].
CPI-613 inhibited growth of various acute myeloid leukemia (AML) cell lines with IC50 values of 16.4, 13.4 and 12.2 μM in HL60, Jurkat and K562 cells, respectively. The treatment of CPI-613 induced apoptosis dose-dependently in OCI-AML3 and K562 cells. In H460 cells cultured in medium containing glutamine and pyruvate as the predominant carbon sources, treatment of CPI-613initiallyreversible ATP level reduction. When the treatment time was above 2 hours, cells became irreversibly committed to death. In the JC-1 localization assay, CPI-613 reduced mitochondrial membrane potential significantly. Besides that, when combined with doxorubicin, the treatment showed synergistic effects in Jurkat and K562 cells [1 and 2].
CPI-613 was proved to have little side-effect toxicity in expected therapeutic dose ranges and be well tolerated at very high doses (the maximum tolerated dose in mice was ca.100 mg/kg). Administration of CPI-613 at dose of 10 mg/kg resulted in significant inhibition of tumor growth in mice bearing H460 human non-small cell lung carcinoma. CPI-613 also caused robust tumor growth inhibition in mouse model of human pancreatic tumor (BxPC-3) xenografts [2].
References:
[1] Pardee T S, Levitan D, Hurd D. Altered mitochondrial metabolism as a target in acute myeloid leukemia. J ClinOncol, 2011, 29(suppl): 6590-6591.
[2] Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoatederivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. Journal of molecular medicine, 2011, 89(11): 1137-1148.
| Cell experiment [1]: | |
|
Cell lines |
NCI-H460 NSCLC human tumor cells |
|
Preparation method |
The solubility of this compound in DMSO is >19.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
50-300 μM |
|
Applications |
In series of tumor cell lines, CPI-613 efficiently killed tumor cells. In H460 human lung cancer cells cultured in medium containing pyruvate and glutamine, CPI-613 significantly reduced ATP levels within less than 60 min and this reduction was initially reversible. After longer treatment times, cells become irreversibly to execute cell death. CPI-613 differentially inhibited PDH activity in normal and tumor cells. |
| Animal experiment [1]: | |
|
Animal models |
nude mouse human tumor xenograft model of a pancreatic tumor cell (BxPC-3) and a non-small cell lung tumor cell (H460) |
|
Dosage form |
25 mg/kg; once weekly; four treatments at 7-day intervals; intraperitoneal injection.10 mg/kg; once weekly, three times weekly, or five times weekly; intraperitoneal injection. |
|
Application |
In human pancreatic (BxPC-3) xenograft carrying nude mouse, CPI-613 significantly inhibited tumor growth and over 40% of treated animals survived until the experiment was terminated at over 8 months (259 days). CPI-613 (10 mg/kg) also inhibited the growth of H460 human non-small cell lung carcinoma and the maximum tolerated dose was ca.100 mg/kg. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoatederivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. Journal of molecular medicine, 2011, 89(11): 1137-1148. |
|
| Cas No. | 95809-78-2 | SDF | |
| Chemical Name | 6,8-bis(benzylsulfanyl)octanoic acid | ||
| Canonical SMILES | C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2 | ||
| Formula | C22H28O2S2 | M.Wt | 388.59 |
| Solubility | 100mg/mL in DMSO, ≥ 93.2 mg/mL in EtOH | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5734 mL | 12.867 mL | 25.7341 mL |
| 5 mM | 514.7 μL | 2.5734 mL | 5.1468 mL |
| 10 mM | 257.3 μL | 1.2867 mL | 2.5734 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)